Skip to main content


Visit the UNC CFAR Biostatistics GitHub at


R package for Serial Limiting Dilution Assay Statistics (SLDAssay)

Power Calculator for Repeated Low-Dose Challenge Studies

R Package for Rank-Sum Power Calculation (wmwpow)

Brief Statistical Safety Checklist


This checklist is designed to help review draft manuscripts, statistical reports, or analysis plans


  • Objective / hypotheses of the study are clearly stated
  • Endpoints are defined, declare endpoints as primary, secondary, and exploratory as appropriate
  • Exposures and covariates are defined
  • Sample size calculation is explained (if applicable)
  • If applicable, randomization and blinding process are explained
  • If applicable, interim stopping guidelines are described
  • All statistical methods are described (with references as needed)
  • Methodological assumptions were reasonably met
  • Reasonable considerations were made for:
    • missing data or attrition (e.g. loss to follow-up)
    • multiple testing or multiple comparisons
    • correlation among observations (e.g. longitudinal or clustered data)
    • small sample sizes (e.g. n<30)
  • Statistical software and version used are stated (e.g. SAS version 9.3, Cary, North Carolina)
  • Statistical type I error probability is declared (e.g. two-sided alpha of 0.05)
  • Clinical trials: trial registration ID included (


Results (including text, tables, figures):

  • Number of decimal places reported appropriately reflects measurement precision
  • Summaries of variability/spread are provided (e.g. SD, IQR)
  • Sample sizes are provided (n=) and missing data are declared when applicable
  • Each p-value is accompanied by a graphical display of data and descriptive statistics. Estimation with precision quantified (e.g., 95% confidence interval) is preferred.
  • If reporting p-values, report specific p-values (p=0.027), rather than p<0.05
  • Use of the word significant should be avoided
  • Figures are clearly explained by a legend and all axes and symbols are appropriately labeled
  • Distorted effect sizes (e.g. by truncation of y-axis) are clearly labeled and justified
  • Units of measurement are stated


  • Discussion conclusions are in agreement with results
  • Limitations of the study design or analytic approach are appropriately stated

For more guidance, refer to standard reporting guidelines (e.g. CONSORT, STROBE, PRISMA, STARD) and the ASA p-value statement (and published updates thereof)

This list was compiled with reference to ‘Instructions for Authors’ at  JAMA, Annals of Internal Medicine, Nature, and Science Magazine.